Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Cancer development and chemo-resistance are often due to impaired functioning of the p53 tumor suppressor through genetic mutation or sequestration by other proteins. In glioblastoma multiforme (GBM), p53 availability is frequently reduced because it binds to the Murine Double Minute-2 (MDM2) oncoprotein, which accumulates at high concentrations in tumor cells. The use of MDM2 inhibitors that interfere with the binding of p53 and MDM2 has become a valid approach to inhibit cell growth in a number of cancers; however little is known about the efficacy of these inhibitors in GBM. We report that a new small-molecule inhibitor of MDM2 with a spirooxoindolepyrrolidine core structure, named ISA27, effectively reactivated p53 function and inhibited human GBM cell growth in vitro by inducing cell cycle arrest and apoptosis. In immunoincompetent BALB/c nude mice bearing a human GBM xenograft, the administration of ISA27 in vivo activated p53, inhibited cell proliferation and induced apoptosis in tumor tissue. Significantly, ISA27 was non-toxic in an in vitro normal human cell model and an in vivo mouse model. ISA27 administration in combination with temozolomide (TMZ) produced a synergistic inhibitory effect on GBM cell viability in vitro, suggesting the possibility of lowering the dose of TMZ used in the treatment of GBM. In conclusion, our data show that ISA27 releases the powerful antitumor capacities of p53 in GBM cells. The use of this MDM2 inhibitor could become a novel therapy for the treatment of GBM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Costa et al. demonstrated that TMZ synergized with the MDM2 PPI inhibitor ISA27 to kill U87-MG cells in vitro”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An increase in p53 expression (but not p21 nor MDM2) was observed in tumors at relapse, potentially associated with the emergence of TP53 mutant tumor cell subpopulations, as it was reported previously (reviewed in [36]).”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Although it has been shown that nutlin3a and other MDM2 PPI inhibitors have single-agent activity in inhibiting the growth of a variety of tumor types including GBM”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
In the citing paper
“and administration of ISA27 alone inhibited growth of GBM flank xenografts.13”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“The cytosolic protein content was determined as previously described [36], and the cytochrome C content was determined using the Platinum Human Cytochrome C ELISA.”
MethodIsolation of mononuclear cells and granulocytes from human blood.
Bøyum, A. (1968) · Scandinavian Journal of Clinical and Laboratory Investigation · Cited by 9,585
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 1×
“The senescence marker, Senescence-associated beta-galactosidase (SA-b-Gal), was detected as previously described [35], and the cells were then washed in PBS (16) and photographed at 1006 magnification.”
MethodIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 2×
“Recently, Nutlin-3, the first potent MDM2 small-molecule inhibitor identified [23], and new D-peptide derivatives [14,24] were reported to be effective at inhibiting GBM cell growth in vitro [14,24,25], suggesting the validity of this experimental approach for the treatment of GBM.”
BackgroundMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 2×
“Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor in humans, and despite technical advances in neurosurgery and clinical neuro-oncology, the prognosis for GBM patients remains very poor [1–8].”
BackgroundBerenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414 · cited 1×
“A graphical assessment of synergy with regard to growth inhibition was performed using isobolographic analysis [39,40].”
MethodGenetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · cited 1×
“Interestingly, MDM2 inhibitors have been reported to induce cancer cell apoptosis even without the concomitant application of genotoxic stimuli [17,18,20].”
Background
Research works printed but not linked: 1
- Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: De Vita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles of oncology. Philadelphia: Lippincott-Raven. 2100–2161.
Cited by
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
“As an illustration, novel MDM2 inhibitors have been reported to inhibit the growth of TP53-wild-type glioblastoma PDCLs, regardless of the tumor MDM2 amplification status [117, 118].”
BackgroundTargeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 299
“Apart from DNA repair systems, it has been demonstrated that other factors, including epidermal growth factor receptor (EGFR) [31], phosphatase and tensin homolog (PTEN) [32], galectin-1 [33], murine double minute 2 (Mdm2) [34], p53 [35], PI3K/AKT/mTOR pathway [36], and sphingosine-1-phosphate/ sphingosine kinases [37…”
BackgroundMolecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
“MDM2 and MDM4 amplifications result in p53 inactivation and MDM2 inhibition has recently emerged as a strategy to restore p53 function [139,140].”
BackgroundGlioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 157
“Most GBMs harbor recurrent molecular alterations disrupting core pathways involved in regulation of growth (EGFR [9,10], PDGFRA [11], FGFR [12,13], mitogen-activated protein kinase (MAPK) [14,15] and phosphoinositide 3-kinase (PI3K) [16,17] signaling pathways), cell cycle [18–21], autophagy [22], DNA repair, and apopt…”
Background
Metadata
- Authors
- Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., Sorriento, D., Del Giudice, C., Iaccarino, G., Novellino, E., & Martini, C.
- Affiliations
- University of Pisa (IT)
- Ospedale Cisanello (IT)
- University of Salerno (IT)
- University of Naples Federico II (IT)
- Corresponding author
- Costa, Barbara
- Martini, Claudia
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-19
- Volume
- 8
- Issue
- 8
- Pages
- e72281
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3747081
- OpenAlex
- W1999920903
- Cited by
- 79
- References
- 53
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 9 · 2018: 12 · 2017: 10 · 2016: 11 · 2015: 6 · 2014: 4
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- glioblastoma, MDM2 inhibitors, p53 reactivation, temozolomide combination therapy, apoptosis, cell cycle arrest, tumor xenografts, small molecule inhibitors, chemoresistance
- MeSH terms
- Animals, Antineoplastic Agents, Brain Neoplasms, Female, Glioblastoma, Humans, Indoles, Mice, Inbred BALB C, Mice, Nude, Protein Binding, Spiro Compounds, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Tumor Burden, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor. https://app.cochat.ai/papers/10.1371/journal.pone.0072281
- The paper
- Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., Sorriento, D., Del Giudice, C., Iaccarino, G., Novellino, E., & Martini, C. (2013). Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor. PLoS ONE. https://doi.org/10.1371/journal.pone.0072281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.